These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31966908)

  • 1. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.
    Kutney K; Donnola SB; Flask CA; Gubitosi-Klug R; O'Riordan M; McBennett K; Sferra TJ; Kaminski B
    World J Hepatol; 2019 Dec; 11(12):761-772. PubMed ID: 31966908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Boutin S; Wielpütz MO; Joachim C; Frey DL; Wege S; Sommerburg O; Kauczor HU; Stahl M; Dalpke AH; Mall MA
    Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745
    [No Abstract]   [Full Text] [Related]  

  • 3. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
    Drummond D; Dana J; Berteloot L; Schneider-Futschik EK; Chedevergne F; Bailly-Botuha C; Nguyen-Khoa T; Cornet M; Le Bourgeois M; Debray D; Girard M; Sermet-Gaudelus I
    J Cyst Fibros; 2022 Mar; 21(2):212-219. PubMed ID: 34454846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
    Gaines H; Jones KR; Lim J; Medhi NF; Chen S; Scofield RH
    J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
    Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
    Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
    [No Abstract]   [Full Text] [Related]  

  • 9. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.
    Thomassen JC; Mueller MI; Alejandre Alcazar MA; Rietschel E; van Koningsbruggen-Rietschel S
    J Cyst Fibros; 2018 Mar; 17(2):271-275. PubMed ID: 29249670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
    Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
    Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years.
    Berges J; Graeber SY; Hämmerling S; Yu Y; Krümpelmann A; Stahl M; Hirtz S; Scheuermann H; Mall MA; Sommerburg O
    Front Pharmacol; 2023; 14():1188051. PubMed ID: 37324488
    [No Abstract]   [Full Text] [Related]  

  • 15. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P; Patidar M; Campbell JD
    Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
    Salazar-Barragan M; Taub DR
    Cureus; 2023 Jul; 15(7):e41697. PubMed ID: 37575762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.
    Hanafin PO; Sermet-Gaudelus I; Griese M; Kappler M; Ellemunter H; Schwarz C; Wilson J; Tan M; Velkov T; Rao GG; Schneider-Futschik EK
    Front Pharmacol; 2021; 12():577263. PubMed ID: 34408649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.